Lōkahi Therapeutics Begins GMP Manufacturing of LT-100 for Potential Osteoarthritis Pain Treatment
Lōkahi Therapeutics Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), has announced the initiation of its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100, a pure honeybee venom-derived biologic being developed as a potential treatment for osteoarthritis pain. The start of GMP production represents an important development milestone for the company as it prepares to advance LT-100 into the next stage of clinical and regulatory development.
The manufacturing campaign is expected to generate clinical trial material that can be used to support upcoming clinical activities and regulatory milestones for the LT-100 program. The company is working toward a potential clinical study designed to evaluate a more patient-friendly method of administering the investigational therapy.
A central element of Lōkahi Therapeutics’ development strategy is the transition from the administration method used in previous efficacy trials. Earlier studies evaluated LT-100 using 15 intradermal injections per treatment. The company is now pursuing a strategy in which LT-100 would be administered as a single subcutaneous injection per visit.
This potential change in administration is intended to simplify treatment and improve the patient experience while maintaining the therapeutic potential of the honeybee venom-derived biologic. The company believes that reducing the number of injections required during each treatment could make the approach more convenient for patients with osteoarthritis knee pain.
GMP Manufacturing Marks an Important Development Milestone
The beginning of GMP manufacturing represents a significant step in the development of LT-100. GMP standards are designed to ensure that medicines and investigational products are consistently manufactured and controlled according to established quality requirements.
For Lōkahi Therapeutics, establishing GMP-manufactured clinical trial material is an important prerequisite for moving the LT-100 program toward future clinical evaluation. The manufacturing campaign will be followed by quality assurance activities and other preparations needed before the company can proceed with its planned clinical development activities.
Erik Emerson, CEO of Glucotrack, said the company had previously outlined its intention to transition LT-100 from 15 intradermal injections per administration to a single subcutaneous injection. He described the start of GMP manufacturing as an important step as the company prepares to determine whether the patient-focused, non-opioid treatment approach can deliver the anticipated clinical outcomes in people with osteoarthritis of the knee.
The shift in administration strategy reflects the company’s focus on balancing potential therapeutic benefits with the practical needs of patients. Treatment burden can be an important consideration in chronic pain conditions, particularly when therapies involve repeated injections. A single-injection approach could potentially make treatment less burdensome if it proves to be clinically appropriate and effective.
LT-100 Targets Osteoarthritis-Related Knee Pain
LT-100 is being developed as a potential treatment for pain associated with osteoarthritis, particularly in patients experiencing knee pain. Osteoarthritis is a common degenerative joint condition that can cause persistent pain, stiffness and limitations in mobility and daily activities.
The LT-100 program is focused on patients whose symptoms have not responded adequately to conservative non-pharmacologic treatments and simple analgesics. The candidate is also being considered for individuals who are unable to tolerate nonsteroidal anti-inflammatory drugs (NSAIDs).
This patient population represents an important area of unmet need because treatment options for osteoarthritis pain can vary depending on disease severity, patient characteristics, previous treatment response and tolerance of available medications. Non-opioid approaches that can provide meaningful pain relief could potentially offer another option for patients who have limited choices.
Lōkahi Therapeutics is therefore evaluating LT-100 as a biologic approach designed to address osteoarthritis pain without relying on opioid-based therapy. However, as an investigational treatment in the company’s current development program, its safety and effectiveness for the proposed administration method still need to be established through appropriate clinical evaluation.
Moving Toward a Single Subcutaneous Injection
One of the most notable aspects of the company’s current strategy is the proposed change in how LT-100 is delivered.
Prior efficacy trials used 15 intradermal injections for each treatment. While this administration method provided clinical development experience with LT-100, requiring numerous injections may create challenges for patients and healthcare professionals.
The company is now preparing to investigate whether a single subcutaneous injection can provide a more convenient treatment experience. Subcutaneous administration involves delivering a medicine into the tissue beneath the skin, rather than directly into the skin at multiple injection sites.
The proposed single-injection approach is described by the company as patient-centric because it has the potential to reduce the number of injections required at each visit. If successful, the strategy could simplify treatment administration and potentially improve the overall experience for patients undergoing therapy for chronic knee pain.
Importantly, the company will need to establish through clinical studies whether the new route and dosing approach can achieve appropriate exposure, safety and therapeutic effects. The planned development work is therefore intended to evaluate the potential of the revised administration strategy rather than assume that results from previous intradermal studies will automatically apply to the new method.
Clinical Trial Preparation Underway
The ongoing GMP manufacturing campaign is expected to produce material intended for use in future clinical development. Once manufacturing activities are completed, the company plans to conduct quality assurance reviews and finalize other clinical preparations.
Regulatory review will also be required before the next clinical stage can begin. The company has indicated that, subject to successful completion of manufacturing, quality activities, clinical preparations and regulatory requirements, it expects to enroll the first patient later this year.
The planned timeline demonstrates that the GMP campaign is one component of a broader development process. Manufacturing must be completed according to appropriate quality standards, and the resulting clinical material must undergo the necessary reviews before it can be used in a clinical study.
The anticipated patient enrollment milestone will represent another important step for the LT-100 program because it would allow the company to begin evaluating the candidate using the proposed single subcutaneous injection approach in a clinical setting.
Background of LT-100
LT-100 is a pure honeybee venom-derived biologic. The candidate has a development history extending beyond the current Lōkahi Therapeutics program.
According to the company, LT-100 was originally developed and approved for marketing in South Korea in 2003 by the Korean Food and Drug Administration (KFDA), which is now known as the Ministry of Food and Drug Safety (MFDS).
The prior development and marketing history provides a foundation for the company’s ongoing work, while the current program is focused on advancing the candidate through its next clinical and regulatory milestones.
The use of honeybee venom as the basis for a therapeutic candidate represents a distinctive approach within pain management research. Lōkahi Therapeutics is seeking to further develop this biologic for patients with osteoarthritis-related knee pain and explore whether an updated administration method can provide a more convenient treatment experience.
Potential Role in Non-Opioid Pain Management
The LT-100 program is also notable because of its positioning as a potential non-opioid treatment for osteoarthritis pain. Chronic musculoskeletal pain remains a significant healthcare challenge, and treatment strategies often involve a combination of lifestyle modifications, physical interventions and medications.
Patients who do not achieve adequate relief from conservative measures may require additional therapeutic options. At the same time, tolerability and safety considerations can limit the use of certain medications, including NSAIDs in some patients.
By developing LT-100 as a non-opioid biologic, Lōkahi Therapeutics is pursuing an alternative approach to pain management. The company’s immediate objective is to determine whether the investigational treatment, delivered through a single subcutaneous injection, can produce clinically meaningful outcomes while maintaining an acceptable safety profile.
The initiation of GMP manufacturing establishes an important foundation for the next phase of LT-100 development. The manufacturing campaign is expected to provide clinical trial material that can support future clinical investigations and regulatory activities.
The company’s immediate priorities include completing GMP manufacturing, conducting quality assurance reviews, completing clinical preparations and obtaining the necessary regulatory review. If these activities proceed successfully, Lōkahi Therapeutics expects to enroll the first patient later this year.
The proposed transition from 15 intradermal injections to one subcutaneous injection represents a key part of the company’s development strategy. Rather than focusing solely on the biological activity of the candidate, the approach also considers the practical experience of patients and healthcare providers.
Ultimately, clinical studies will determine whether the revised administration method can deliver the desired therapeutic outcomes in osteoarthritis of the knee. The results will be important in determining the future development path of LT-100.
For now, the start of GMP manufacturing marks meaningful progress for Lōkahi Therapeutics and Glucotrack. By advancing production of clinical trial material and preparing for additional clinical evaluation, the company is moving LT-100 closer to its next development milestones. If the program successfully demonstrates safety and efficacy, the candidate could potentially provide a new non-opioid option for patients with knee osteoarthritis pain who have inadequate responses to existing conservative treatments or cannot tolerate commonly used therapies.
About Lōkahi Therapeutics™
Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai² platform and ai² Futures Lab execution model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit www.lokahithera.com. For more information about the ai² Futures Lab program, please visit www.ai2futureslab.com.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) operates Lōkahi and, through its subsidiary Glucotrack Technologies, Inc., is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.